Heart Failure & Cardiac Repair stem cell therapy — your questions answered (2026)

About stem cell therapy for Heart Failure & Cardiac Repair

Heart failure is a clinical syndrome in which impaired cardiac contraction, relaxation or both causes symptoms and circulatory dysfunction. Causes include myocardial infarction, hypertension, cardiomyopathy and valvular disease. Mesenchymal stromal cells (MSCs) and extracellular vesicles are being studied for possible effects on inflammation, fibrosis, angiogenesis and cell survival observed mainly in preclinical models. Those mechanisms have not established clinically meaningful cardiac repair in people. The registry table on this page lists relevant studies and their current recruitment status.

The evidence for Heart Failure & Cardiac Repair

Human heart-failure cell-therapy studies vary substantially by cell product, ischaemic or non-ischaemic cause, route, comparator and endpoint. Some studies report changes in imaging, exercise capacity or biomarkers, but consistent improvement in hospitalisation or survival has not been established for a marketed cell product. Exploratory subgroup findings should not be converted into a predictable response rate. No pooled response rate is published here because the studies are too heterogeneous for a single figure to be meaningful. The registered studies and their own prespecified endpoints are listed in the registry table on this page.

Private investigational heart-failure cell procedures can involve separate charges for catheterisation, imaging, laboratory testing, monitoring, travel and standard cardiology care. Prices do not indicate regulatory approval or expected benefit, and repeat dosing is not an established standard. Patients should request an itemised written quote and verify which costs are paid by the study sponsor, insurer and patient. Guideline-directed heart-failure treatment and transplant or device evaluation must not be delayed for an experimental procedure.

Can stem cells repair the heart?

Cell therapy for Heart Failure & Cardiac Repair may be offered as an individualised programme, but regulatory status depends on the product, processing, indication and jurisdiction. It is currently investigational. Verify authorisation status, cell source, release testing and clinical evidence for the specific proposal.

Which heart conditions qualify?

Schedules vary by the exact product, protocol, route, monitoring needs and clinical context. Request the proposed schedule and its evidence before making travel arrangements.

Is it infused or injected?

Eligibility depends on the protocol's inclusion and exclusion criteria and an appropriately qualified clinician's assessment. An online checklist cannot determine candidacy or replace medical advice.

EU cost?

The partner-published indicative range for an Heart Failure & Cardiac Repair programme is €3,000–€8,000 for treatment. Request a current written quotation and compare product, dose, visits, inclusions and follow-up before using country ranges as a benchmark.

Sources & further reading

We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.

• Open clinical trials for Heart Failure & Cardiac Repair (ClinicalTrials.gov) ↗
• Peer-reviewed research on PubMed ↗
• ISSCR patient guide — what to ask ↗
• FDA consumer warning on stem-cell therapies ↗
• EMA — advanced-therapy (ATMP) framework ↗

← Back to Heart Failure & Cardiac Repair overview · Heart Failure & Cardiac Repair cost →